A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
John F. Gerecitano(Memorial Sloan Kettering Cancer Center), Matthew S. Davids(Dana-Farber Cancer Institute), Lori A. Gressick(AbbVie (United States)), Andrew W. Roberts(The Royal Melbourne Hospital), Lindsay Wagner(AbbVie (United States)), Thomas J. Kipps(University of California San Diego), John M. Pagel(University of Washington), Rod Humerickhouse(Abbott Fund), Sari Heitner Enschende(AbbVie (United States)), Brad S. Kahl(UW Health University Hospital), John F. Seymour(The Royal Melbourne Hospital), Ming Zhu(AbbVie (United States)), William G. Wierda(University of Maryland, Baltimore), Mary Ann Anderson(The Royal Melbourne Hospital), Soham D. Puvvada(University of Arizona), Su Young Kim(AbbVie (United States)), Martin Dunbar(AbbVie (United States))
Cited by 74
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k